Scientific editorial illustration of Scutellaria baicalensis root, membrane lipids and iron-linked lipid peroxidation
Geroprotect Blog

Geroprotect research note · Evidence review

The Root That Learned It Twice

Baicalein, Huang Qin, ferroptosis and the limits of human Phase I safety data

Abstract

Baicalein is a 5,6,7-trihydroxyflavone associated with the root of Scutellaria baicalensis, or Huang Qin. Its most interesting evidence sits at very different levels: short Phase I pharmacokinetic studies in healthy adults; cell and animal models of lipid peroxidation; a cell-free protein-aggregation experiment; cultured-cell work on stress-induced senescence; and lifespan experiments in worms and flies. Those levels cannot be merged into one claim.

The human record shows that several single- and multiple-dose regimens were studied over short periods. It does not establish efficacy, long-term safety, disease prevention or lifespan extension. Ferroptosis work around ALOX12 and GPX4 is mechanistically substantial but preclinical—and baicalein is not unique among the flavonoids in touching ferroptosis. The well-known alpha-synuclein result is cell-free. A stress-induced astrocyte experiment supports a possible senomorphic research hypothesis, not a validated human action. This reviewed edition retains what is unusual about the molecule while removing exclusivity, synergy and chronic-safety claims that the evidence cannot carry.

01 · Identity

One root, two chemical forms, and a specialised pathway

Baicalein is the aglycone 5,6,7-trihydroxyflavone. Baicalin is baicalein 7-O-glucuronide: the same flavone scaffold with a glucuronic-acid group at the 7-position. That change affects polarity, transport and metabolism. In a rat pharmacokinetic experiment, oral baicalin was partly hydrolysed before absorption, while oral baicalein appeared predominantly as glucuronide and sulfate conjugates in plasma.1 The human Phase I papers likewise measured baicalin as a major metabolite after baicalein dosing.2

That does not support the simple instruction that one form is always “better absorbed” or more effective in people. Gut metabolism, conjugation, enterohepatic cycling, formulation and the endpoint being measured all matter. It does support precise labelling: a product containing baicalein should not be described as though it contained baicalin, and a paper about baicalin cannot be silently cited as evidence for baicalein.

The title of this note comes from the plant rather than from a therapeutic claim. A 2016 genetic and biochemical study found that S. baicalensis roots use a specialised pathway to produce 4′-deoxyflavones. Root-specific enzyme isoforms route cinnamic acid through pinocembrin and chrysin toward compounds that include baicalein, whereas aerial flavones use the more familiar pathway.3 Evolution arrived at a second biosynthetic route. That is elegant plant biology; it is not evidence that the finished molecule slows human aging.

02 · Human pharmacology

Two development tracks, four Phase I publications—and no efficacy result

Baicalein is sometimes described as the only flavonoid in the formula taken through Phase I. That statement is not defensible. Published Phase I or dose-finding programmes exist for other flavonoids, including EGCG, genistein and quercetin.456 Baicalein remains notable because two development programmes produced four useful pharmacokinetic and tolerability papers. Notable is different from unique.

The first development track

In 2014, 72 healthy adults entered a randomized, double-blind, single-ascending-dose study of baicalein chewable tablets from 100 to 2,800 mg. Eleven treatment-related adverse events were reported; all were mild and resolved without treatment, and no serious adverse event occurred. Laboratory monitoring did not identify a liver- or kidney-toxicity signal during the study.2

A 2016 multiple-ascending-dose study enrolled 36 healthy volunteers; 33 completed it. Regimens were 200, 400 or 800 mg once on days 1 and 10 and twice daily on days 3 through 9. Forty-four adverse events occurred in 23 participants, and the authors reported the tested regimens as generally well tolerated. Exposure rose with dose, dose proportionality was inconclusive, and steady state was reached by day 8.7

The second development track

A 2021 publication combined three randomized single-dose investigations spanning 100 to 800 mg. Among 80 participants evaluable for safety, 56 adverse events occurred in 32 people; all were mild and resolved without medical intervention. Elevated high-sensitivity C-reactive protein and triglycerides were the most common reported events. Food changed the pharmacokinetic profile, and exposure increased less than proportionally across the tested range.8

A separate 2021 multiple-dose study randomized 36 healthy participants to 200, 400 or 600 mg tablets or placebo. Dosing occurred once on days 1 and 10 and three times daily on days 4 through 9. Eight drug-related adverse events included proteinuria, elevated triglycerides, elevated high-sensitivity C-reactive protein, one elevated ALT and one elevated AST. Events were mild and resolved; one unrelated fever was moderate.9

A randomized Phase IIa influenza-fever study was registered as NCT03830684, with an estimated enrolment of 180. As checked on 14 July 2026, the record was marked “Unknown status,” was last verified in February 2019, and had no results posted. It therefore provides no efficacy evidence.

03 · Ferroptosis

A compelling preclinical mechanism that is not exclusive to baicalein

Ferroptosis is a regulated cell-death programme driven by iron-dependent phospholipid peroxidation. In a 2016 natural-product screen, baicalein inhibited erastin-induced ferroptosis in pancreatic cancer cells, limited ferrous-iron accumulation, glutathione depletion and lipid peroxidation, and reduced GPX4 degradation.10

A 2024 study extended the mechanism in cisplatin- and folic-acid-induced kidney-injury models. In cells and rodents, baicalein reduced ALOX12 expression and phospholipid peroxidation. Molecular docking and surface plasmon resonance supported direct baicalein–ALOX12 binding; ALOX12 silencing produced a similar regulatory effect, and the dedicated ALOX12 inhibitor ML355 produced comparable results.11 The ML355 comparison belongs to this kidney-injury paper—not to the earlier cardiomyocyte experiment.

The boundaries are as important as the mechanism. This is not a human intervention result, and ferroptosis is not a hole that only baicalein fills. A direct comparison found that both baicalein and luteolin reduced ischemia/reperfusion-associated ferroptosis in rat cardiomyocytes.12 Separate preclinical papers report ferroptosis modulation by quercetin, apigenin and fisetin.131415 Different compounds, tissues, injuries and directions of effect cannot be ranked as one universal “ferroptosis potency” table.

Context can even reverse the direction. In colorectal-cancer cells and xenografts, baicalein promoted rather than prevented ferroptosis through a JAK2/STAT3/GPX4 model.16 That does not prove a cancer treatment or selective protection of healthy human tissue. It shows that pathway language without model context can mislead.

04 · Proteostasis

Alpha-synuclein fibrils moved in a test tube; patients were not treated

A 2004 cell-free study found that low-micromolar baicalein and its oxidized products inhibited alpha-synuclein fibril formation. Preformed fibrils fragmented in the presence of baicalein, and the reaction produced stable soluble oligomers. Tyrosine-to-phenylalanine substitutions abolished binding, supporting specific chemical involvement rather than a generic antioxidant explanation.17

The experiment is technically interesting and relevant to protein-aggregation research. It does not show that an oral dose reaches the human brain at the required free concentration, safely disaggregates pathological fibrils in vivo, changes Parkinson’s disease, or even guarantees that every resulting oligomer is biologically benign. A later proposal involving disruption of a fibril salt bridge came from molecular-dynamics simulations, not a clinical or biochemical validation study.18

05 · Senescence

A senomorphic hypothesis, not a demonstrated human identity

Baicalein is sometimes described categorically as “not a senolytic” because it was not a hit in the well-known flavonoid screen that highlighted fisetin. That reasoning is invalid: baicalein was not tested in that screen. Absence from the experiment is not a negative result.

The positive evidence is also narrower than the label. In hydrogen-peroxide-stressed T98G astrocyte-like cells and primary neonatal-rat astrocytes, baicalein reduced several senescence and SASP-associated measures and affected JAK2/STAT1/NF-κB signalling and leucine metabolism.19 This supports further work on stress-induced senescence and inflammatory output. It does not establish that baicalein is a senomorphic in humans, that it suppresses a SASP after oral supplementation, or that it improves an aging outcome.

A colon-cancer senescence paper sometimes attributed to baicalein tested baicalin instead.20 It therefore cannot be used as baicalein evidence.

06 · Lifespan

Positive worms and flies; no mammalian lifespan test

In 2025, baicalein extended lifespan and improved motility, oxidative-stress resistance and lipofuscin measures in Caenorhabditis elegans. Genetic and reporter experiments implicated reduced DAF-2 insulin/IGF-1 signalling, nuclear DAF-16 and increased sod-3 expression.21 An earlier study in female Drosophila melanogaster reported increases in mean and maximum lifespan at two dietary concentrations and protection in hydrogen-peroxide and paraquat stress models.22

Those are organism-level longevity results, but they are still invertebrate results. No published mammalian lifespan experiment or NIA Interventions Testing Program result for baicalein was identified as of 14 July 2026. No human trial has measured lifespan, healthspan, frailty or a validated biological-aging outcome.

07 · Safety interpretation

Purified baicalein and skullcap products are not the same exposure

LiverTox’s skullcap record summarizes rare reports of clinically apparent liver injury, generally involving botanical materials or multi-ingredient products and, in some cases, uncertainty about species, adulteration or co-exposures. The controlled Phase I studies concern defined baicalein tablets. Neither record should be used to erase the other, and neither establishes the long-term safety of isolated baicalein or the finished Geroprotect formula.

Interaction claims need the same discipline. Evidence involving whole Scutellaria extracts, baicalin, isolated baicalein or an in-vitro transporter assay cannot be transferred automatically between exposures. The present clinical programme does not provide a complete interaction map for daily baicalein. People using prescription medicines—especially anticoagulants, drugs with a narrow therapeutic index, or medicines monitored through liver function—should ask a qualified clinician or pharmacist before use. Pregnancy, breastfeeding, planned surgery and existing liver or kidney disease also warrant clinical review.

08 · Formula context

What 360 mg in Essentials II does—and does not—mean

A full six-tablet daily serving of Geroprotect Essentials II contains 360 mg of baicalein. The label names the aglycone, not baicalin and not a crude Huang Qin extract. That amount falls within dose ranges used in short Phase I protocols, but this is only a contextual comparison. It does not prove bioequivalence, chronic safety, target engagement, synergy with luteolin or any other ingredient, disease prevention, or longer life.

StatementEvidence boundary
Baicalein has human pharmacokinetic dataSupported by short Phase I single- and multiple-dose studies in healthy adults.
Baicalein modulates ferroptosisSupported in defined cell and animal models; not demonstrated as a clinical effect.
Baicalein is a human senomorphicUnproven; the supporting work is a preclinical stress-induced senescence model.
Baicalein improves Parkinson’s diseaseUnproven; the pivotal alpha-synuclein work is cell-free and Phase I did not test efficacy.
Baicalein extends lifespanShown in worms and flies, not mammals or humans.
The Essentials II combination is synergisticUntested. Pathway overlap is a formulation rationale, not a clinical result.

Questions

Frequently asked questions

What is the difference between baicalein and baicalin?

Baicalein is the aglycone; baicalin is its 7-O-glucuronide. They can interconvert through intestinal and human metabolism, but they are not interchangeable names and evidence for one should not be attributed automatically to the other.

Has 360 mg of baicalein been proven safe for long-term daily use?

No. Short Phase I studies included doses around and above 360 mg, but their regimens and durations do not establish chronic safety for 360 mg daily or safety of the complete 13-ingredient Essentials II formula.

Is baicalein the only Geroprotect flavonoid linked to ferroptosis?

No. Baicalein has interesting ALOX12- and GPX4-related data, but luteolin, quercetin, apigenin and fisetin also have model-specific preclinical ferroptosis findings. No head-to-head human comparison exists.

Is baicalein a senolytic?

That has not been established. Baicalein was absent from the famous flavonoid screen often cited as a negative test. A separate stress-induced astrocyte study supports a possible senomorphic research hypothesis, not a validated human effect.

Does baicalein treat Parkinson’s disease or cancer?

No clinical efficacy has been demonstrated for either. Alpha-synuclein work was cell-free; oncology findings are preclinical and context-dependent. This article does not support a disease-treatment claim.

Sources

References

  1. Xing J, et al. Interaction of baicalin and baicalein with antibiotics in the gastrointestinal tract. Journal of Pharmacy and Pharmacology. 2005;57:743–750. PMID 15969929.
  2. Li M, et al. Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects. Journal of Ethnopharmacology. 2014;156:210–215. PMID 25219601.
  3. Zhao Q, et al. A specialized flavone biosynthetic pathway has evolved in the medicinal plant, Scutellaria baicalensis. Science Advances. 2016;2:e1501780. PMID 27152350.
  4. Chow HH, et al. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and Polyphenon E. Cancer Epidemiology, Biomarkers & Prevention. 2001;10:53–58. PMID 11205489.
  5. Ullmann U, et al. Safety, tolerability, and pharmacokinetics of single ascending doses of synthetic genistein (Bonistein) in healthy volunteers. Advances in Therapy. 2005;22:65–78. PMID 15943224.
  6. Mehta PA, et al. Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia. Blood Advances. 2025;9:1927–1939. PMID 39820512.
  7. Pang H, et al. Multiple-ascending-dose pharmacokinetics and safety evaluation of baicalein chewable tablets in healthy Chinese volunteers. Clinical Drug Investigation. 2016;36:713–724. PMID 27352310.
  8. Dong R, et al. Safety, tolerability, pharmacokinetics, and food effect of baicalein tablets in healthy Chinese subjects. Journal of Ethnopharmacology. 2021;274:114052. PMID 33753147.
  9. Li L, et al. Safety, tolerability, and pharmacokinetics of oral baicalein tablets in healthy Chinese subjects: a multiple-ascending-dose study. Clinical and Translational Science. 2021;14:2017–2024. PMID 34156161.
  10. Xie Y, et al. Identification of baicalein as a ferroptosis inhibitor by natural product library screening. Biochemical and Biophysical Research Communications. 2016;473:775–780. PMID 27037021.
  11. Guo S, et al. Baicalein alleviates cisplatin-induced acute kidney injury by inhibiting ALOX12-dependent ferroptosis. Phytomedicine. 2024;130:155757. PMID 38805781.
  12. Wang IC, et al. Baicalein and luteolin inhibit ischemia/reperfusion-induced ferroptosis in rat cardiomyocytes. International Journal of Cardiology. 2023;375:74–86. PMID 36513286.
  13. Wang Y, et al. Quercetin alleviates acute kidney injury by inhibiting ferroptosis. Journal of Advanced Research. 2021;28:231–243. PMID 33364059.
  14. Shao C, et al. Epileptic brain fluorescent imaging reveals apigenin can relieve the myeloperoxidase-mediated oxidative stress and inhibit ferroptosis. Proceedings of the National Academy of Sciences USA. 2020;117:10155–10164. PMID 32327603.
  15. Li D, et al. Fisetin attenuates doxorubicin-induced cardiomyopathy in vivo and in vitro by inhibiting ferroptosis through SIRT1/Nrf2 signalling. Frontiers in Pharmacology. 2022;12:808480. PMID 35273493.
  16. Lai JQ, et al. Baicalein triggers ferroptosis in colorectal cancer cells via blocking the JAK2/STAT3/GPX4 axis. Acta Pharmacologica Sinica. 2024;45:1715–1726. PMID 38684798.
  17. Zhu M, et al. The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. Journal of Biological Chemistry. 2004;279:26846–26857. PMID 15096521.
  18. Yao Y, et al. Baicalein exhibits differential effects and mechanisms towards disruption of alpha-synuclein fibrils with different polymorphs. International Journal of Biological Macromolecules. 2022;220:316–325. PMID 35981677.
  19. Gao L, et al. Baicalein delays H2O2-induced astrocytic senescence through inhibition of senescence-associated secretory phenotype, suppression of the JAK2/STAT1/NF-κB pathway, and regulation of leucine metabolism. ACS Chemical Neuroscience. 2021;12:2320–2335. PMID 34152720.
  20. Wang Z, et al. Baicalin induces cellular senescence in human colon cancer cells via upregulation of DEPP and the activation of Ras/Raf/MEK/ERK signaling. Cell Death & Disease. 2018;9:217. PMID 29440765. Compound identity: baicalin, not baicalein.
  21. Zhao C, Schrapel D, Schaefer M. Baicalein enhances longevity and healthspan of C. elegans through the insulin/IGF-1 signalling pathway. MedComm. 2025;6:e70543. PMID 41415716.
  22. Duan D, et al. Baicalein prolongs the lifespan of Drosophila melanogaster through antioxidation activity. Yao Xue Xue Bao. 2016;51:1401–1406. PMID 29924517.

Quality you can check

Every badge links to the document behind it: manufacturer certificates, certificates of analysis for all 26 actives, and our own promises about the formula.

Huazhen Biotechnology (Shenzhen) holds ISO 22000:2018 certificate 015FSMS2400550 and HACCP certificate 015HACCP2400460, both valid until 2 December 2027. These are manufacturer system papers, not a product certificate. The earlier papers 150FSMS2200001 and 150HACCP2200001 ended in March 2025 and are not shown as valid. Halal certificates cover raw materials from our suppliers; Geroprotect Essentials is not registered as a halal product. Food supplement. Read the current product label before use.

Bought from Geroprotect? Leave an honest review:Review us on TrustpilotReview us on GoogleReview on Amazon.aeReviews are optional and never rewarded. More about reviews.
Scroll to Top